Navigation Links
Chromos enters into an Arrangement Agreement
Date:8/7/2008

ous assumptions. Although our management believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that a forward-looking statement or information herein will prove to be accurate. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include amongst others the risks and uncertainties involved in satisfying the conditions to close the Arrangement. Should one or more of these risks and uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements and information.

Although we have attempted to identify factors that may cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond our control. As actual results and future events could differ materially from those anticipated in such statements and information, readers should not place undue reliance on forward-looking statements or information. Except as may be required by law, we undertake no obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise. All forward-looking statements and information made herein are qualified by this cautionary statement.


'/>"/>
SOURCE Chromos Molecular Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Chromos enters into loan and lending arrangements
3. Chromos provides shareholder update
4. Chromos Announces Full Revocation of Cease Trade Orders
5. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
6. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
7. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
8. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
9. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... Inc. (NYSE: MDT ) has submitted ... and Drug Administration (FDA) for the use of ... system (including a newly developed catheter) for use ... delivered intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... 21 Startech,Environmental Corp. (OTC Bulletin Board: ... Company, announced today that the,EnviroSafe Industrial Services ... its original plans for its new recycling-facility ... to install three Plasma Converters Systems,purchased last ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that it has elected to suspend,enrolment in ... its Vascular Wrap,product candidate in patients undergoing surgery ... an imbalance of infections that have,been observed between ...
... A group of German,investors is about to acquire up ... purchasing price of up to EUR 750,000. The acquisition,will be ... subscribed,to by the investors. It will become effective after the ... and after the capital increase will,have been entered in the ...
Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Hospital Research Institute (OHRI) and the University of Ottawa have ... Spinal muscular atrophy (SMA), the leading inherited cause of death ... student Melissa Bowerman have found that an enzyme called RhoA ... and blocking this enzyme can greatly increase survival. The study ...
... 2010 Using a novel light activation technique, Scripps Research ... a modest ability to fight specific proteins into virtual protein ... capable of inactivating nearby proteins when triggered by light, could ... researchers with a new set of research tools and options. ...
... of psychopaths appear to be wired to keep seeking a ... The research uncovers the role of the brain,s reward system ... understanding what drives these individuals. "This study underscores ... Dr. Francis S. Collins, director of the National Institutes of ...
Cached Biology News:Study opens new avenue for developing treatments for genetic muscle-wasting disease 2Light activated 'warhead' turns modest molecules into super protein killers 2Light activated 'warhead' turns modest molecules into super protein killers 3Psychopaths' brains wired to seek rewards, no matter the consequences 2Psychopaths' brains wired to seek rewards, no matter the consequences 3
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... 384-well reaction module is used for nucleic ... with an interchangeable, 384-well reaction module (5-20 ... and control and ramp rates that are ... the iCycler base with 384-well reaction module, ...
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
Biology Products: